Potent Natural Opioid Peptide for Pain Relief & Neurological Research

Dermorphin 5mg is a naturally occurring opioid peptide originally isolated from the skin secretions of South American frogs (Phyllomedusa sauvagei). It is an extremely potent mu-opioid receptor agonist, estimated to be 30–40 times stronger than morphine in pain relief, while requiring significantly smaller doses.

Due to its strong analgesic and neuromodulatory effects, Dermorphin has been studied in the context of severe pain management, opioid receptor research, and neurological modulation. However, it remains experimental and restricted to research use due to its potency and potential for dependency.

Key Benefits

• Powerful Analgesic Effect – Provides potent pain relief beyond traditional opioids.
• Neuromodulatory Properties – Influences opioid receptor pathways for research in brain function.
• Lower Dose Requirement – Effective at microgram-level doses compared to milligrams of morphine.
• Potential in Chronic Pain Research – Explored as an option for severe, treatment-resistant pain.
• Unique Natural Origin – Expands peptide-based approaches to neurological and pharmacological science.

Who Can Benefit

• Researchers studying pain management alternatives to opioids
• Medical teams exploring severe or chronic pain solutions under controlled trials
• Pharmacologists investigating mu-opioid receptor dynamics
• Professionals in neurological and peptide research fields

Usage & Dosage

• Administration: Injectable (subcutaneous or intramuscular), only in research or clinical settings
• Potency: Effective in microgram (µg) doses
• Typical Research Dose: 0.5–2 mg daily (divided into small injections; highly variable)
• Supervision: Must be physician- or researcher-controlled due to risk of respiratory depression and dependency

Best Timing

• Research/Clinical Protocols Only – Timing depends on study design or patient condition
• Severe Pain Applications – Often investigated for nighttime relief to improve sleep quality

Cycle Duration

• Short-Term Protocols: For acute pain or limited trials
• Chronic Use Risks: Dependency potential makes long-term administration unsuitable outside controlled studies

⚠️DISCLAIMER

Syncom products are intended for professional use only and must be administered under the strict supervision of a licensed healthcare professional.

Our formulations and sterile solutions are not intended for self-administration and are not a replacement for prescribed medical treatments. Always consult a qualified healthcare provider before initiating peptide therapy to ensure safe and appropriate use.

Syncom assumes no liability for misuse, unsupervised application, or use outside professional settings.